RhumbLine Advisers: Corcept Therapeutics CORT Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 28.8 M | Compra |
249,543
+61,771
| +33% | +USD 6.64 M | 0.02% | 555 |
|
|
2026
Q2 | USD 16.3 M | Venta |
187,772
-2,926
| -2% | -USD 177 k | 0.01% | 858 |
|
|
2026
Q1 | USD 7.69 M | Compra |
190,698
+4,010
| +2% | +USD 150 k | 0.01% | 1193 |
|
|
2025
Q4 | USD 6.5 M | Venta |
186,688
-1,530
| -0.8% | -USD 120 k | 0.01% | 1259 |
|
|
2025
Q3 | USD 15.6 M | Compra |
188,218
+1,747
| +0.9% | +USD 126 k | 0.01% | 869 |
|
|
2025
Q2 | USD 13.7 M | Venta |
186,471
-14,930
| -7% | -USD 1.08 M | 0.01% | 916 |
|
|
2025
Q1 | USD 23 M | Compra |
201,401
+565
| +0.3% | +USD 34.4 k | 0.02% | 620 |
|
|
2024
Q4 | USD 10.1 M | Venta |
200,836
-1,996
| -1% | -USD 105 k | 0.01% | 1051 |
|
|
2024
Q3 | USD 9.39 M | Compra |
202,832
+44
| +0% | +USD 1.56 k | 0.01% | 1096 |
|
|
2024
Q2 | USD 6.59 M | Venta |
202,788
-3,956
| -2% | -USD 108 k | 0.01% | 1242 |
|
|
2024
Q1 | USD 5.21 M | Venta |
206,744
-5,549
| -3% | -USD 131 k | 0.01% | 1400 |
|
|
2023
Q4 | USD 6.9 M | Compra |
212,293
+7,035
| +3% | +USD 193 k | 0.01% | 1232 |
|
|
2023
Q3 | USD 5.59 M | Compra |
205,258
+454
| +0.2% | +USD 13.1 k | 0.01% | 1276 |
|
|
2023
Q2 | USD 4.56 M | Venta |
204,804
-5,980
| -3% | -USD 138 k | 0.01% | 1432 |
|
|
2023
Q1 | USD 4.57 M | Compra |
210,784
+12,976
| +7% | +USD 284 k | 0.01% | 1381 |
|
|
2022
Q4 | USD 4.02 M | Compra |
197,808
+1,054
| +0.5% | +USD 26.4 k | 0.01% | 1404 |
|
|
2022
Q3 | USD 5.04 M | Compra |
196,754
+9,881
| +5% | +USD 264 k | 0.01% | 1220 |
|
|
2022
Q2 | USD 4.44 M | Compra |
186,873
+5,417
| +3% | +USD 118 k | 0.01% | 1303 |
|
|
2022
Q1 | USD 4.09 M | Compra |
181,456
+2,895
| +2% | +USD 61.6 k | 0.01% | 1442 |
|
|
2021
Q4 | USD 3.54 M | Venta |
178,561
-1,064
| -0.6% | -USD 21.6 k | ﹤0.01% | 1567 |
|
|
2021
Q3 | USD 3.54 M | Venta |
179,625
-39,987
| -18% | -USD 837 k | ﹤0.01% | 1566 |
|
|
2021
Q2 | USD 4.83 M | Venta |
219,612
-3,832
| -2% | -USD 85.3 k | 0.01% | 1446 |
|
|
2021
Q1 | USD 5.32 M | Compra |
223,444
+5,534
| +3% | +USD 148 k | 0.01% | 1371 |
|
|
2020
Q4 | USD 5.7 M | Compra |
217,910
+63
| +0% | +USD 1.33 k | 0.01% | 1282 |
|
|
2020
Q3 | USD 3.79 M | Venta |
217,847
-22,385
| -9% | -USD 357 k | 0.01% | 1324 |
|
|
2020
Q2 | USD 4.04 M | Venta |
240,232
-13,891
| -5% | -USD 195 k | 0.01% | 1331 |
|
|
2020
Q1 | USD 3.02 M | Compra |
254,123
+2,100
| +0.8% | +USD 26 k | 0.01% | 1323 |
|
|
2019
Q4 | USD 3.05 M | Compra |
252,023
+19,240
| +8% | +USD 268 k | 0.01% | 1556 |
|
|
2019
Q3 | USD 3.29 M | Compra |
232,783
+179
| +0.1% | +USD 2.2 k | 0.01% | 1428 |
|
|
2019
Q2 | USD 2.59 M | Compra |
232,604
+4,416
| +2% | +USD 49.2 k | ﹤0.01% | 1581 |
|
|
2019
Q1 | USD 2.68 M | Venta |
228,188
-2,778
| -1% | -USD 34.5 k | 0.01% | 1540 |
|
|
2018
Q4 | USD 3.09 M | Compra |
230,966
+46,944
| +26% | +USD 620 k | 0.01% | 1386 |
|
|
2018
Q3 | USD 2.58 M | Compra |
184,022
+775
| +0.4% | +USD 10.8 k | 0.01% | 1521 |
|
|
2018
Q2 | USD 2.88 M | Compra |
183,247
+11,790
| +7% | +USD 205 k | 0.01% | 1468 |
|
|
2018
Q1 | USD 2.82 M | Compra |
171,457
+3,400
| +2% | +USD 63 k | 0.01% | 1404 |
|
|
2017
Q4 | USD 3.04 M | Compra |
168,057
+78,700
| +88% | +USD 1.43 M | 0.01% | 1374 |
|
|
2017
Q3 | USD 1.72 M | Compra |
89,357
+1,685
| +2% | +USD 25.1 k | ﹤0.01% | 1700 |
|
|
2017
Q2 | USD 1.04 M | Compra |
87,672
+15,494
| +21% | +USD 168 k | ﹤0.01% | 1940 |
|
|
2017
Q1 | USD 791 k | Compra |
72,178
+2,492
| +4% | +USD 21.9 k | ﹤0.01% | 2031 |
|
|
2016
Q4 | USD 506 k | Compra |
69,686
+9,684
| +16% | +USD 75.9 k | ﹤0.01% | 2222 |
|
|
2016
Q3 | USD 390 k | Compra |
60,002
+3,139
| +6% | +USD 18.3 k | ﹤0.01% | 2347 |
|
|
2016
Q2 | USD 310 k | Compra |
56,863
+8,272
| +17% | +USD 43 k | ﹤0.01% | 2510 |
|
|
2016
Q1 | USD 227 k | Venta |
48,591
-40
| -0.1% | -USD 156 | ﹤0.01% | 2674 |
|
|
2015
Q4 | USD 242 k | Compra |
48,631
+4,855
| +11% | +USD 21.9 k | ﹤0.01% | 2692 |
|
|
2015
Q3 | USD 165 k | Compra |
43,776
+1,951
| +5% | +USD 9.9 k | ﹤0.01% | 2853 |
|
|
2015
Q2 | USD 251 k | Venta |
41,825
-1,650
| -4% | -USD 10.1 k | ﹤0.01% | 2763 |
|
|
2015
Q1 | USD 243 k | Compra |
43,475
+10,100
| +30% | +USD 36.6 k | ﹤0.01% | 2729 |
|
|
2014
Q4 | USD 100 k | Venta |
33,375
-8,510
| -20% | -USD 25.9 k | ﹤0.01% | 2961 |
|
|
2014
Q3 | USD 112 k | Sin cambios |
41,885
| – | – | ﹤0.01% | 2913 |
|
|
2014
Q2 | USD 117 k | Venta |
41,885
-1,620
| -4% | -USD 4.78 k | ﹤0.01% | 2954 |
|
|
2014
Q1 | USD 190 k | Venta |
43,505
-2,600
| -6% | -USD 9.09 k | ﹤0.01% | 2787 |
|
|
2013
Q4 | USD 148 k | Venta |
46,105
-200
| -0.4% | -USD 404 | ﹤0.01% | 2904 |
|
|
2013
Q3 | USD 74 k | Venta |
46,305
-491
| -1% | -USD 866 | ﹤0.01% | 2955 |
|
|
2013
Q2 | USD 81 k | Compra |
+46,796
| Nuevas | +USD 84.1 k | ﹤0.01% | 3272 |
|
Otros fondos que tienen CORT en su portafolio
Posición de RhumbLine Advisers en CORT: resumen de T3 2026
RhumbLine Advisers aumentó su participación en Corcept Therapeutics (CORT) en 33% durante T3 2026, al comprar aproximadamente USD 6.64 M y elevar la posición a 249,543 acciones con un valor de USD 28.8 M. La posición representa 0.02% del portafolio y ocupa el puesto #555.
RhumbLine Advisers reportó por primera vez una posición en CORT en T2 2013 y desde entonces la ha mantenido en 54 trimestres. Al cierre de T3 2026, 503 fondos que sigue Wall St. Rank mantienen una posición en CORT.
- Al cierre de T3 2026, RhumbLine Advisers tenía 249,543 acciones de Corcept Therapeutics con un valor de USD 28.8 M.
- RhumbLine Advisers compró 61,771 acciones de Corcept Therapeutics en T3 2026, por un monto estimado de USD 6.64 M.
- Corcept Therapeutics representó el 0.02% del portafolio de RhumbLine Advisers en T3 2026 y fue su posición número 555.
- RhumbLine Advisers reportó por primera vez una posición en Corcept Therapeutics en T2 2013 y desde entonces la ha mantenido en 54 trimestres.
- Al cierre de T3 2026, 503 fondos que sigue Wall St. Rank tenían Corcept Therapeutics en su portafolio.
Según el informe 13F de RhumbLine Advisers correspondiente a T3 2026, presentado el 10 nov 2026.